Welcome to our dedicated page for Prime Medicine SEC filings (Ticker: PRME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Prime Medicine, Inc. (Nasdaq: PRME) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a public biotechnology company, Prime Medicine uses forms such as Form 8-K, Form 10-Q, Form 10-K and proxy statements to report material events, financial results, governance matters and other information related to its Prime Editing gene editing platform and pipeline.
Recent Form 8-K filings for Prime Medicine have covered topics such as quarterly financial results and business highlights, preliminary cash and investment balances, underwritten public offerings of common stock, option repricing approvals, changes in executive leadership, and the posting of updated corporate presentations. These filings help investors understand how the company is funding research and development for programs in Wilson’s Disease, Alpha-1 Antitrypsin Deficiency, Cystic Fibrosis and other areas, as well as how it manages equity compensation and corporate governance.
Definitive proxy materials, such as the company’s DEF 14A, describe matters submitted to stockholders, including proposals related to equity plans and special meetings. Over time, periodic reports on Forms 10-K and 10-Q (when available) provide more detailed information on Prime Medicine’s operations, risk factors, research and development expenses, and other aspects of its business as a biotechnology issuer focused on Prime Editing-based therapies.
On Stock Titan, Prime Medicine filings are updated as they are made available through EDGAR. AI-powered tools summarize key points from lengthy documents, helping users quickly identify items such as new financing arrangements, changes in leadership roles, special stockholder meetings, and other material events disclosed in Forms 8-K and related exhibits. Users can also review filings that may include information about stock-based compensation, equity offerings, and other capital structure changes relevant to PRME shares.
Prime Medicine, Inc. (PRME) – Form 4 insider transaction
Director and 10% owner David R. Liu disclosed the purchase of 21,000 shares of Prime Medicine common stock on 23-Jun-2025. The trade was executed under a previously adopted Rule 10b5-1 plan dated 3-Mar-2025, indicating it was pre-scheduled rather than opportunistic.
The weighted-average purchase price was $2.162 per share, with individual trades occurring between $2.06 – $2.25. Following the transaction, Liu’s direct ownership increased to 20,219,945 shares, an incremental addition of roughly 0.10 % to his existing stake.
No derivative securities were reported, and no sales occurred. While the absolute dollar value of the purchase (~$45,400) is modest relative to Liu’s overall holding, insider buying—especially by a high-ownership director—can be interpreted as a vote of confidence in the company’s prospects at current price levels.